<div id="readability-page-1">Johnson Investment Counsel Inc. lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 38.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 28,930 shares of the medical equipment provider's stock after selling 17,924 shares during the period. Johnson Investment Counsel Inc.'s holdings in Zimmer Biomet were worth $2,850,000 at the end of the most recent quarter.<div>Get Zimmer Biomet alerts:</div><ul><li>A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH</li></ul>Other institutional investors and hedge funds have also bought and sold shares of the company. Key Financial Inc boosted its stake in shares of Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 163 shares during the period. Cullen Frost Bankers Inc. raised its stake in Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider's stock valued at $29,000 after purchasing an additional 116 shares during the period. Root Financial Partners LLC purchased a new position in Zimmer Biomet in the 3rd quarter worth approximately $31,000. Cary Street Partners Investment Advisory LLC boosted its stake in Zimmer Biomet by 83.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider's stock worth $30,000 after purchasing an additional 149 shares during the period. Finally, Mather Group LLC. purchased a new stake in Zimmer Biomet during the 3rd quarter valued at approximately $36,000. 88.89% of the stock is owned by institutional investors. <h2>Analyst Upgrades and Downgrades</h2>Several equities analysts have recently commented on ZBH shares. Wells Fargo &amp; Company boosted their target price on shares of Zimmer Biomet from $93.00 to $98.00 and gave the stock an &#34;equal weight&#34; rating in a report on Wednesday. UBS Group reiterated a &#34;sell&#34; rating and issued a $89.00 price target on shares of Zimmer Biomet in a report on Wednesday. BTIG Research reiterated a &#34;buy&#34; rating and issued a $112.00 price target on shares of Zimmer Biomet in a research note on Tuesday. Sanford C. Bernstein increased their price objective on shares of Zimmer Biomet from $97.00 to $99.00 and gave the company a &#34;market perform&#34; rating in a report on Friday, January 9th. Finally, Johnson Rice set a $112.00 target price on Zimmer Biomet in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of &#34;Hold&#34; and a consensus price target of $106.45.<ul><li>Intuitive Surgical Leads the Pack in Robotic Surgery Innovation</li></ul>Check Out Our Latest Stock Report on Zimmer Biomet<h2>Zimmer Biomet News Summary</h2>Here are the key news stories impacting Zimmer Biomet this week:<ul> <li>Positive Sentiment: Q4 beat — ZBH reported EPS of $2.42 and revenue of ~$2.24B (up ~10.9% YoY), beating consensus and driven by strong demand for hip and knee devices. Reuters: Zimmer Biomet beats quarterly estimates</li> <li>Positive Sentiment: New buyback announced — Management unveiled a fresh repurchase program alongside the results, which supports the share price and signals confidence in cash generation. Yahoo Finance: ZBH up after earnings beat and buyback</li> <li>Positive Sentiment: Index/sector lift — The earnings beat contributed to broader healthcare index flows and was noted as lifting Russell 1000 Healthcare sentiment. Index/sector recognition can amplify demand for the stock. Kalkine: Beats estimates, lifts Russell 1000 Healthcare</li> <li>Positive Sentiment: Analyst moves — Several shops nudged targets or reaffirmed ratings (price-target increases to $98 at Citigroup and Wells Fargo; BTIG reiterated a $112 buy target), lending some near-term support. Benzinga: Analyst updates</li> <li>Neutral Sentiment: Guidance is conservative but roughly in-line — FY2026 EPS guidance was set at $8.30–$8.45 and revenue guidance around $8.4–$8.6B, essentially in line with consensus but underscored by cautious language that tempers upside expectations. MSN: Tops Q4 but measured on 2026 guidance</li> <li>Neutral Sentiment: U.S. salesforce overhaul — Management flagged a U.S. salesforce restructuring and transition that should improve execution long-term but adds near-term uncertainty and drove a cautious tone on the call. Yahoo Finance: Q4 deep dive — salesforce overhaul</li> <li>Negative Sentiment: Margins and headwinds — Management acknowledged margin pressure (some contraction noted in the quarter) and called out tariffs and cost dynamics as potential drags on 2026 profit expansion. These factors could limit upside to profitability. Zacks: Q4 earnings &amp; margin commentary</li> <li>Negative Sentiment: Cautious management tone — While results beat, the measured guidance and commentary imply limited near-term upside and increased execution risk during the transition, which could cap multiple expansion. MSN: Q4 earnings call transcript</li> </ul><h2>Zimmer Biomet Price Performance</h2><ul><li>2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead</li></ul>ZBH stock opened at $95.51 on Thursday. Zimmer Biomet Holdings, Inc. has a 52 week low of $84.59 and a 52 week high of $114.44. The firm has a market capitalization of $18.93 billion, a P/E ratio of 26.98, a price-to-earnings-growth ratio of 2.34 and a beta of 0.62. The company has a fifty day simple moving average of $90.01 and a two-hundred day simple moving average of $95.64. The company has a quick ratio of 1.39, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm had revenue of $2.24 billion for the quarter, compared to analysts' expectations of $2.22 billion. During the same period in the prior year, the company earned $2.31 EPS. The business's revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year. <h2>Zimmer Biomet Announces Dividend</h2>The business also recently disclosed a quarterly dividend, which was paid on Friday, January 30th. Stockholders of record on Tuesday, December 30th were paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend was Tuesday, December 30th. Zimmer Biomet's dividend payout ratio (DPR) is presently 27.12%. <h2>Zimmer Biomet Company Profile</h2> (Free Report)Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures. The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.<h2>Featured Articles</h2><ul><li>Five stocks we like better than Zimmer Biomet</li><li>Is THIS the Next Big Money Rush?</li><li>Wall Street Legend Names #1 Stock of 2026 Live On-Camera</li><li>ISPC: From Small Cap to Life Sciences Market Disruptor!</li><li>The Crash Has Already Started (Most Just Don’t See It Yet)</li><li>Is Elon Preparing for a Silver Shock?</li></ul><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpCSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpCSA"/>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.<h2>Should You Invest $1,000 in Zimmer Biomet Right Now?</h2>Before you consider Zimmer Biomet, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zimmer Biomet wasn't on the list.While Zimmer Biomet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here </div>

SBIO

Johnson Investment Counsel Inc. reduced its stake in Zimmer Biomet Holdings, Inc. by 38.3% in Q3, now holding 28,930 shares valued at $2.85 million. Other institutional investors have also adjusted their positions, with Key Financial Inc. increasing its stake by 164.6%. Analysts have mixed ratings on Zimmer Biomet, with target prices ranging from $89 to $112. The stock has an average rating of "Hold" and a consensus price target of $106.45. Recent earnings beat expectations, but guidance remains cautious due to potential margin pressures and restructuring efforts.

Market Beat

Johnson Investment Counsel Inc. Lowers Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH